| Prev Close | 6.66 |
| Open | 6.70 |
| Day Low/High | 6.08 / 6.80 |
| 52 Wk Low/High | 4.22 / 8.81 |
| Volume | 1.58M |
Ardelyx, Inc. (ARDX)
6.67
0.01
0.15
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 90.25B |
| Market Cap | 619.10M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
This Market Action Is Not Creating Many Setups
Until market conditions shift, I won't be making any sizable buys.
Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers
The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Ardelyx Has Big Potential
This small-cap company's shares are half where they ended 2015.
Profiting on Small-Cap Biotech Earnings
Don't trade the headline numbers, but cash in on those traders that do.
